WELCOME TO THIS BSC SESSION.
I THINK PAT IF YOU WOULD LIKE WE
CAN GO AHEAD AND GET STARTED AND
I WILL ASK THE AV PERSON TO ITES
SLIDES.
PERFECT.
THANK YOU ALL SO VERY MUCH,
WELCOME TO THIS BSC MEETING
TODAY.
I'D LIKE TO REMIND THE BSC
MEMBERS THAT WE ARE IN A SESSION
FOR DR. LOWY'S TALK AND IT IS
BEING VIDEOCAST LIVE AS WELL AS
BEING RECORDED FOR FUTURE
VIEWING FOR THE PUBLIC.
AND FOR THOSE THAT ARE ON FROM
THE PUBLIC, I WOULD LIKE TO WISH
WHO MAY WISH TO EXPRESS THEIR
VIEWS REGARDING ANY OF THE ITEMS
THAT ARE DISCUSSED DURING
DR. LOWY'S TALK, YOU MAY DO SO
BY WRITING DR. MEHRDAD TONDRAVI,
THE SECRETARY WITHIN 10 DAYS OF
THE MEETING AND ANY WRITTEN
STATEMENTS YOU SUBMIT WILL
RECEIVE CAREFUL CONSIDERATION
AND WILL BE RESPONDED TO IN A
TIMELY FASHION AND WITH THAT I
WOULD LIKE TO INTRODUCE DR. DOUG
LOWY THIS MORNING, THE ACTING
NCI DIRECTOR WHO WILL BE OPENING
OUR SESSION.
DR. LOWY.
>> THANKS VERY MUCH PAT.
WELL, GOOD MORNING TO EVERYONE.
IF I COULD HAVE THE FIRST SLIDE
I WANT TO FIRST, FOR THOSE OF
YOU WHETHER YOU KNOW ME OR NOT,
MY LAB HAS BEEN IN CCR FOR MANY
YEARS AND I CONTINUE TO HAVE A
LAB THERE.
I ALSO AM AN ADJUNCT
INVESTIGATOR IN DCEG, AND
INTERACT WITH QUITE A FEW
INVESTIGATORS IN DCEG AS WELL
AND MY LAB WILL BE UNDERGOING
SITE VISIT IN 4 MONTHS IN
NOVEMBER, SO IN MANY WAYS, YOU
KNOW I AM VERY MUCH A PART OF
WHAT THE BSC IS INVOLVED IN
REVIEWING, ET CETERA AND I
REALLY APPRECIATE WHAT ALL OF
YOU ARE DOING.
IF I COULD HAVE THE NEXT SLIDE.
I'M GOING TO TOUCH ON 4
DIFFERENT TOPICS AND WILL PLAN
TO BE TALKING FOR NO MORE THAN
20 MINUTES SO THAT THERE'S AMPLE
TIME FOR QUESTIONS AND COMMENTS
FROM YOU.
I'M GOING TO TALK ABOUT
CONTINUITY OF NCI LEADERSHIP,
SINCE THIS IS THE FIRST TIME I'M
TALKING WITH YOU AS ACTING
DIRECTOR THIS TIME.
THEN SOME NEAR TERM INITIATIVES,
OF SOMETHING ABOUT THE RPG POOL
AND ITS RELATIONSHIP TO THE FY23
NCI BUDGET.
THAT IS NEXT YEAR'S BUDGET.
AND THEN THE CANCER MOONSHOT
ABOUT WHAT'S BEEN HAPPENING WITH
THE CURRENT ASPECT OF THE MOON
SHOT AND TRYING TO THINK FORWARD
FOR THE NEW PARTS.
IF I COULD HAVE THE NEXT SLIDE.
THIS BASICALLY SHOWS YOU WHAT
HAS HAPPENED OVER THE LAST 12
YEARS WITH NCI DIRECTORS HAROLD
VARMIS, NED SHARPLESS AND ME.
THIS IS MY THIRD ONCE IN A
LIFETIME OPPORTUNITY TO BE THE
ACTING DIRECTOR OF NCI AND I
WANT YOU TO UNDERSTAND THAT I'VE
BEEN THE PRINCIPAL DEPUTY
DIRECTOR FOR THE PAST 12 YEARS.
SO THERE'S ACTUALLY BEEN A LOT
OF CONTINUITY.
I DO NOT VIEW MY ROLE AS MAINLY
BEING ACTING.
I THINK THAT I MAKE AS MANY
DECISIONS THAT NEED TO BE MADE
AS HAROLD AND NED DID BECAUSE
THERE ARE SO MANY IMPORTANT
QUESTIONS THAT ARISE FOR NCI,
CANCER RESEARCH AND THE CANCER
COMMUNITY BUT I DON'T DO THIS IN
A VACUUM.
THE NEXT SLIDE, SHOWS YOU THAT
WE HAVE REALLY A TERRIFIC GROUP
WITH THE NCI LEADERSHIP TEAM AND
THEY HAD BEEN IN PLACE FOR QUITE
A WHILE, MOST OF THEM.
THE NEXT SLIDE, NOW, TURNS THE
ISSUE OF SOME CURRENT AND NEAR
FUTURE NCI ACTIVITIES.
I'M GOING TO SAY A LITTLE BIT
MORE ABOUT THE CANCER MOONSHOT
IN A FEW MINUTES, BUT WE REALLY
WANT TO BE ABLE TO CONTINUE TO
FUND THE MOST PROMISING
INITIATIVES OF THE INITIAL
CANCER MOONSHOT WHICH IS GOING
ON, THE GOAL OF HAVING A SOFT
LANDING AND WE ALSO HAVE A YEAR
NOW OF PLANNING FOR THE PHASE.
THE CANCER CENTERS, WE ARE IN
THE PROCESS OF FINISHING PHASES
1 AND 2 FOR THE CANCER CENTER
SUPPORT GRANTS AND SO WE'RE
CLOSE TO TRYING TO MAKE
DECISIONS ABOUT WHAT TO DO GOING
FORWARD FOR PHASE 3 WITH THE
RENEWALS FOR THE SUPPORT GRANTS
OVER THE NEXT FEW YEARS.
AND THEN FOR THE FREDERICK
NATIONAL LAB, WE WANT TO SELECT
AT LEAST 1 NEW SIGNATURE PROJECT
AT THE FREDERICK NATIONAL LAB TO
GO ALONG WITH THE GRANTS
INITIATIVE AND THEN AS WELL, THE
X-RAY CRYSTALLOGRAPHY THAT IS
GOING ON THERE.
NEXT SLIDE.
ON MY 12th DAY AS THE ACTING
DIRECTOR, I PARTICIPATED IN A
HEARING OF THE HOUSE
APPROPRIATIONS SUBCOMMITTEE AND
CANCER RESEARCH COMMENTS WERE
MADE ON BOTH SIDES OF THE AISLE
THAT WERE VERY COMPLIMENTARY AND
CHAIR DELAURO, AND RANKING
MEMBER COLE CAME TO TALK WITH ME
AFTER THE MEETING WAS OVER AND
THAT'S SHOWNOT BOTTOM LEFT SIDE
BECAUSE I'VE KNOWN BOTH OF THEM
AS A RESULT OF HAVING BEEN
DIRECTOR PREVIOUSLY.
THE NEXT SLIDE SHOWS YOU WHAT
HAS HAPPENED OVER THE LAST FEW
YEARS.
IN ORANGE HAS BEEN THE
PRESIDENT'S BUDGET AND IN THE
TALE BLUE IS THE ENACTED BUDGET
FOR THAT GIVEN YEAR AND FOR EACH
YEAR IN THE LAST 5 YEARS, NOTE
THAT THE ACTUAL APPROPRIATED
BUDGET HAS BEEN HIGHER THAN THAT
OF THE PRESIDENT'S BUDGET.
AND I BRING THIS UP BECAUSE THE
FY23 BUDGET, ACTUALLY FOR THE
PRESIDENT'S BUDGET IS ACTUALLY
$200 MILLION LOWER THAN OUR FY22
ENACTED BUDGET.
MY EXPECTATION IS--MY
EXPECTATION IS THAT IT WILL BE
HIGHER BUT HOW MUCH HIGHER
REALLY REMAINS TO BE DETERMINED.
THERE'S STRONG BI PARTISAN
SUPPORT FOR CANCER RESEARCH AND
ALSO CONGRESS HAS DECLINED TO
CUT FUNDING EVEN IN CHALLENGING
BUDGET CYCLES.
LAST MONTH THE HOUSE
APPROPRIATIONS SUBCOMMITTEE
PROPOSED A BILL OF 7.4 BILLION
DOLLARS FOR NCI, THAT INCLUDES
$216 MILLION FOR THE CANCER
MOONSHOT WHICH IS WHAT WAS
PROPOSED SEVERAL YEARS AGO FOR
FY23.
AND THIS, IF IF WERE ENACKED,
WOULD REPRESENT A
466 MILLION-DOLLAR INCREASE FOR
NCI OVER THE APPROPRIATED AMOUNT
FOR FY22.
I'M MENTIONING THIS IN PART
BECAUSE WE WANT TO PRIORITIZE
THE FUNDING OF THE RPG POOL AS
WE HAVE BEEN DOING OVER THE LAST
FEW YEARS.
THIS YEAR IN FY22, IT WAS
NECESSARY FOR US FOR EXPERIENCED
INVESTIGATORS TO STAY AT THE
11th PERCENTILE FOR THE PAY
LINE BUT WE'RE HOPING THAT IF IN
FY23, IF THERE WERE
APPROXIMATELY 400 MILLION-DOLLAR
INCREASE, WE COULD GO TO THE
12th PERCENTILE AND IF THERE
WERE A 500 MILLION-DOLLAR
INCREASE, WE THINK WE COULD GO
TO THE 13th PERCENTILE.
OBVIOUSLY THIS DEPENDS IN PART
ON THE NUMBER OF GRANT
APPLICATIONS AND SOME OTHER
FACTORS, BUT THIS WILL ONLY
HAPPEN AS A RESULT OF THE CANCER
ADVOCACY COMMUNITY, THE CANCER
RESEARCH COMMUNITY AND MANY
OTHERS IN THE CANCER COMMUNITY,
POINTING OUT HOW IMPORTANT
CANCER RESEARCH IS FOR MAKING
PROGRESS IN THIS AREA.
NEXT SLIDE.
I JUST WANT TO YOU TO SEE WHAT
WE HAVE DONE OVER THE LAST FEW
YEARS IN PRIORITIZING THE RPG
POOL.
AS SHOWN ON THE LEFT, THE TOTAL
BUDGET FOR THE RPG POOL, THE
PORTION WENT FROM 41 TO 44% AND
THAT'S BECAUSE THE RPGs, WE
HAVE TAKEN ABOUT 53% OF THE
BUDGET INCREASE AND PUT IT INTO
THE RPG POOL WITH ONLY 47% OF
THE REMAINDER.
THE NEXT SLIDE SHOWS YOU WHAT
THE FUNDING HAS BEEN FROM THE
RPG POOL, NEXT SLIDE, PLEASE, ON
THE RIGHT EARLY STAGE
INVESTIGATORS WERE GIVEN A
5-POINT ADDITIONAL LEVEL FOR
THEIR PAY LINE AND WE'VE GONE
FROM 84 AWARDS IN 2016 TO 134 IN
2021, WE DON'T HAVE THE NUMBERS
YET OF COURSE FOR FY22 BECAUSE
IT'S STILL GOING ON.
AND IF YOU LOOK ON THE LEFT,
THIS IS FOR TOTAL R01 AND R37
AWARDS, WE MADE 650 AWARDS IN
2016 AND WE'RE ABLE TO MAKE 811
AWARDS IN 2020-2021.
NEXT SLIDE.
AND THIS IS 1 SLIDE ABOUTLET
IMPORTANCE OF CANCER HEALTH
DISPARITIES AND JUST AS RELATED
TO RESEARCH AND TRAINING.
AND THIS SHOWS YOU THE ACTUAL
DOLLAR AMOUNTS AS WELL AS THE
PERCENTAGE OF THE NCI BUDGET
THAT HAS GONE FOR HEALTH
DISPARITIES RESEARCH AND
TRAINING AND I HOPE YOU CAN
APPRECIATE THAT OVER THE LAST 20
YEARS, THERE HAS BEEN A
SUBSTANTIAL INCREASE AND OF
COURSE, WE AND OTHERS HAVE AN
EVEN GREATER FOCUS ON
DISPARITIES RELATED RESEARCH AND
INCLUSION AND INCLUSION OF
GROUPS.
NEXT SLIDE.
MY LAST TOPIC IS TO TALK ABOUT
THE CANCER MOONSHOT AND I HAVE A
FEW SLIDES HERE.
FIRST, 1 SLIDE ABOUT CURRENT
ACTIVITIES OF THE CANCER
MOONSHOT.
THERE HAVE BEEN IN THE FIRST 2
YEARS MORE THAN 2000
PUBLICATIONS JUST UNDER 50
CLINICAL TRIALS AND MORE THAN 30
PATENT FILINGS.
ON THE RIGHT IT SHOWS THAT NEXT
YEAR, FY23 IS THE LAST YEAR FOR
FUNDING OF THIS ASPECT OR THIS
PHASE OF THE CANCER MOONSHOT AND
AS I SAID EARLIER WE SHOULD TRY
TO SUPPORT THE MOST PROMISING
INITIATIVES FROM THE CANCER
MOONSHOT WHILE DEVELOPING
ADDITIONAL ACTIVITIES TO MEET
CHALLENGING NEW GOALS.
THE NEXT SLIDE, IS ACTUALLY 1 OF
THOSE ACTIVITIES.
MEGAN CLARK AND NICO
[INDISCERNIBLE] AND THEIR
COLLEAGUES FROM DCEG PUBLISHED A
HIGH PROFILE PAPER 2 MONTHS AGO
ABOUT RACIAL AND ETHNIC DRVESES
IN HYSTERECTOMY CORRECTED
UTERINE CORPUS MORTALITY AND
HISTOLOGIC SUBTYPE AND THIS HAS
GOTTEN A LOT OF PUBLICITY AS
WELL AS MEETINGS INVOLVING GUIN
OICOLOGGIC ONCOLOGISTS.
BUT WHAT THE TAKE HOME MESSAGE
IS THAT UTERINE DEATH RATES HAVE
BEEN RISING IN CONTRAST TO MOST
OTHER AREAS OF CANCER MORTALITY.
AND THEIR HIGHEST AMONG BLACK
WOMEN IN THE UNITED STATES.
BLACK WOMEN ARE 2 TIMES AS
LIKELY TO DIE OF UTERINE CANCER
AND THEREFORE IT
DISPROPORTIONATELY AFFECTS BLACK
WOMEN BUT ALSO NOW HISPANIC
WOMEN.
BETWEEN 2010 AND 2017, THERE WAS
A 3.5% INCREASE IN MORTALITY FOR
BLACK WOMEN AND A 6.7% FOR
HISPANIC WOMEN.
AND SHOWN ON THE RIGHT, AN
URGENT NEED FOR NEW RESEARCH IN
THE AFFECTED POPULATIONS.
I AM TALKING ABOUT THIS IN THE
CONTEXT OF THE CANCER MOONSHOT
BECAUSE NCI RECOGNIZED ALREADY
AT THE BEGINNING OF THE CANCER
MOONSHOT THAT THIS WAS A SERIOUS
DISPARITY AND SO 1 MOON SHOT
ACTIVITY IS ACTUALLY TO DO
RESEARCH FOCUS ESPECIALLY ON
BLACK WOMEN WHO DEVELOP UTERINE
CANCER.
AND WE ARE GOING TO BE HAVING
MEETINGS, THE FIRST 1 IS
TOMORROW TO TALK ABOUT WHAT ARE
THE RESEARCH GAPS HERE AND HOW
CAN WE TRY TO NARROW THOSE GAPS
SO THAT SEVERAL YEARS FROM NOW,
WE WILL HOPEFULLY BE DOING A
BETTER JOB IN UNDERSTANDING AND
APPROACHING THIS CANCER.
NEXT SLIDE.
SO IN FEBRUARY PRESIDENT BIDEN
TALKED ABOUT THE CANCER MOONSHOT
IN ITS NEXT PHASE.
AND FROM MY PERSPECTIVE, THERE
REALLY ARE 3 MAIN ACTIVITIES, 1
IS TO CUT THE CANCER DEATH RATE
AT LEAST IN HALF WITHIN 25
YEARS.
TWO, TO TRANSFORM THE MEANING OF
CANCER, AND 3 TO ADDRESS CANCER
ASSOCIATED INIQUITIES.
LET ME TALK ABOUT EACH OF THEM
BRIEFLY.
I HAVE ASKED A GROUP OF
INVESTIGATORS IN DCEG AND CCR TO
LOOK AT THE PROJECTIONS FOR
VARIOUS CANCERS, THE 1S WITH THE
HIGHEST MORTALITY RATES AND TO
LOOK 25 YEARS FORWARD, HOW DO
THINGS LOOK?
HOW REALISTIC IS IT?
WHAT DO WE NEED TO DO IN ORDER
TO CUT THE CANCER DEATH RATE IN
HALF AND I'M HOPING THAT WITHIN
A COUPLE OF MONTHS THAT THEY
WILL BE ABLE TO SUBMIT A PEER
REVIEW PUBLICATION ABOUT THIS
AREA.
TRANSFORM THE MEANING OF CANCER.
TO ME, EVEN IF WE CAN CUT THE
CANCER DEATH RATE BY MORE THAN
HALF WITHIN 25 YEARS, IF THERE
REMAIN MANY CANCERS WHERE WE
CAN'T CHANGE THE OUTLOOK FOR
PATIENT WHO IS DEVELOP THOSE
CANCERS, WE WILL NOT HAVE
TRANSFORMED THE MEANING OF
CANCER.
AND THEN ADDRESSING CANCER
ASSOCIATED INIQUITIES, IF WE
STILL HAVE MAJOR GAPS BETWEEN
DIFFERENT RACIAL AND ETHNIC
GROUPS, AND THEIR MORTALITY
RATES IN CANCER, WE ALSO WILL
NOT HAVE ACHIEVED THE GOAL OF
THE NEXT PHASE OF THE CANCER
MOONSHOT.
SO MY LAST SLIDE IS REALLY
TALKING--NEXT SLIDE, PLEASE IS
REALLY TO TALK ABOUT WHAT WE
ENVISION FOR TRYING TO
ACCOMPLISH THE NEW GOALS OF THE
CANCER MOONSHOT.
FIRST WE NEED TO INVEST IN THE
PIPELINE OF NEW DRUGS FOR CANCER
PREVENTION, INTERCEPTION AND
TREATMENT.
SECOND, WE NEED TO GREATLY
EXPAND CLINICAL TRIALS TO SPEED
THE EVALUATION OF CANDIDATE
INTERVENTIONS IN DIVERSE
POPULATIONS, RACIAL EETHNIC,
GEOGRAPHIC FOR EXAMPLE.
THIRD, WE NODE TO INSURE
EQUITABLE HEALTHCARE DELIVERY OF
CURRENT AND NEW STANDARDS OF
CARE.
AND THIS WILL REQUIRE A LOT OF
IMPLEMENTATION RESEARCH AND
FOURTH, WE NEED TO INCREASE THE
DIVERSITY OF CANCER RESEARCH AND
THE CANCER CARE WORKFORCE TO
MORE CLOSELY RESEMBLE THE
COMMUNITIES THAT WE SERVE.
SO THIS IS REALLY A HIGH LEVEL
OVERVIEW, IF I COULD HAVE THE
LAST SLIDE OF WHAT I ENVISION
FOR NCI OVER THE NEXT PERIOD.
THIS NEEDLESS TO SAY IS JUST THE
TIP OF THE ICEBERG.
BUT I WANTED TO LEAVE ENOUGH
TIME FOR YOU ON THE BSC TO ASK
ME QUESTIONS OR MAKE COMMENTS
ABOUT THIS.
THANKS VERY MUCH.
>> THANK YOU SO VERY MUCH
DR. LOWY.
SO, THE FLOOR IS OPEN TO THE BSC
MEMBERS TO ASK QUESTIONS.
>> I SEE STEVE LABOUDY AND
BARBARA AND STEVE, HOW ABOUT IN
THAT ORDER?
NDOUG.
THANK YOU THAT WAS A GREAT
OVERVIEW AND CONGRATULATIONS AND
I GUESS SOME CONDOLENCES ON ONCE
AGAIN HAVING TO OCCUPY THIS
POSITION ALTHOUGH I CAN TELL YOU
FROM--
>> IT IS A GREAT--IT IS A GREAT
JOB AND A GREAT HONOR TO BE ABLE
TO LEAD THE NCI.
>> WELL, I KNOW THAT AND--
>> DON'T FEEL SORRY FOR ME.
>> I NEVER DO.
AND YOU HAVE TREMENDOUS ENERGY
AND COMPASSION AND FOCUS AND I
KNOW FROM MY OTHER CANCER CENTER
DIRECTOR COLLEAGUES WE'RE VERY,
VERY HAPPY THAT YOU'RE AT THE
HELM DURING THIS PERIOD.
SO MY QUESTION WAS ABOUT GIVEN
THE CHALLENGES THAT WE AWNCH
FACE EACH YEAR WITH RESPECT TO
PAY LINES ISSUES SUPPORTING
INITIATIVES LIKE THE MOON SHOT,
ALL OF THE CHALLENGES WE HAVE
WITH THE NEW MOON SHOT IN TERMS
OF THE IMPACT WE WOULD LIKE TO
MAKE, AND THE FACT THAT NOW, ARP
A-H HAS BEEN AUTHORIZED BUT HAS
BEEN RESOURCED WITH A--I THINK
IF I'M REMEMBERING CORRECTLY A
2.7 BILLION DOLLAR BUDGET AND
THAT FURTHER IT IS NOT WITHIN
NIH BUT IS A SEPARATITY WITHIN
HHS.
ONE, ARE YOU CONCERNED ABOUT THE
RESOURCE DEPLOYMENT AND HOW THAT
MAY OR MAY NOT IMPACT THE NCI'S
MISSION AND 2, ARE THEIR
MECHANISMS THAT WILL BE IN PLACE
TO F A SOME ACCORD NATION
AT LEAST WITH THE DEPLOYMENT OF
RESOURCES, I RECOGNIZE THAT ARP
A-H IS MORE THAN JUST CANCER BUT
I KNOW THAT CANCER IS 1 OF THE
TOP 3 INITIATIVES THAT THE
ADMINISTRATION HAS IDENTIFIED IN
ITSELF JUSTIFICATION FOR
LAUNCHING A NEW ENTERPRISE.
SO WHAT ARE YOUR THOUGHTS ON
THAT?
>> STEVE, THANKS VERY MUCH.
LET ME FIRST CLARIFY THAT WHAT
WAS APPROPRIATED IN FY22 WAS 1
BILLION DOLLAR.
THE 2.7 BILLION IS WHAT THE
HOUSE SUBCOMMITTEE HAD IN THEIR
MARK UP.
BUT THAT'S FOR FY23, IT'S
UNCLEAR WHAT WILL HAPPEN.
LET ME FIRST TELL YOU THAT BOTH
CHAIR [INDISCERNIBLE] AS WELL AS
RANKING MEMBER COLE IN THEIR
OPENING REMARKS AT THE HEARING
WHERE I PARTICIPATED SAID ON THE
1 HAND THAT THEY WERE
ENTHUSIASTIC ABOUT ARP A-H BUT
ON THE OTHER HAND THEY WERE
WORRIED THAT ARP A-H'S FUNDING
MIGHT COMPETE WITH THE FUNDING
OF NIH.
SO I'M JUST TELLING YOU WHAT
THEY SAID.
ARP A H IS AN UNUSUAL SITUATION
IN A COUPLE OF RESPECTS.
THE FIRST IS THAT ALTHOUGH
THERE'S AN APPROPRIATION THERE
ISN'T AN AUTHORIZATION YET AND
SOME OF THE SKIRMISHES THAT YOU
WERE TALKING ABOUT, STEVE ARE
UNRESOLVED ISSUES THAT
PRESUMABLY WILL BE RESOLVED WHEN
ARP A H IS AUTHORIZED.
IT IS UNCLEAR WHAT ARP A H IS
GOING TO DO EXACTLY WHARKS
PROPORTION OF ITS RESEARCH WOULD
BE ORIENTED TOWARDS CANCER AND
WHAT KINDS OF CANCER RESEARCH IT
MIGHT WANT TO DO.
WE WOULD BE ENTHUSIASTIC ABOUT
WORKING TOGETHER WITH ARP A H IN
AREAS OF CANCER RESEARCH AND WE
ASSUME THAT THERE WILL BE
REASONABLE ACCORD NATION BETWEEN
THE 2 BUT THERE'S NO
INFRASTRUCTURE THERE, ET CETERA.
I CAN'T GIVE YOU MORE
SPECIFICITY THAN THAT.
>> THANK YOU DOUG.
>> I THINK NANCY DAVIDSON.
>> YES.
>> DOUG, I DID.
WELCOME BACK AND STEVE ASKED ME
QUESTION, SO THANK YOU FOR YOUR
ANSWER, I APPRECIATE IT.
>> OKAY, BARBARA?
>> WELL, WELCOME BACK AND OF
COURSE THE HPV WORLD WELCOMES
YOU A SUPER AMOUNT BUT MAB I
MISSED THIS BUT GIVEN THE
APPROPRIATION, I DIDN'T REALLY
UNDERSTAND WHAT THE DIFFERENCE
WAS BETWEEN INTERNAL AND
EXTERNAL FUNDING BECAUSE
CERTAINLY THAT PAY LINE I THINK
AMONG OUR INVESTIGATORS HAS
BECOME REALLY FRUSTRATING IN
THAT WE DON'T REALLY SEE A
CHANGE DRAMATICALLY SO I'M JUST
WONDERING AGAIN, GIVEN WHAT
NCI'S APPROPRIATED BUT IS THE
ACTUAL DISTRIBUTION BETWEEN
INTERNAL AND EXTERNAL FUNDING?
>> ABOUT 85% OF OUR FUND SUGGEST
EXTRAMURAL.
OKAY AND ABOUT 15% IS
INTRAMURAL.
>> AND THAT'S BEEN PRETTY
STEADY.
>> I WOULD SAY IT'S GONE DOWN A
BIT, OKAY?
IN OTHER WORDS, THE INTRAMURAL
PERCENTAGE HAS GONE DOWN A BIT
BECAUSE WE'VE BEEN TRYING TO
PRIORITIZE THE RPG POOL AND OF
COURSE, THERE'S--YOU KNOW 1 OF
THE REASONS THAT WE NEED TO FUND
MANY OTHER AREAS OF THE NCI
BUDGET IS BECAUSE THEY ALSO
SUPPORT TRAINING, RESEARCH, ET
CETERA, THEY'RE ALSO VERY
IMPORTANT.
SO, I THINK IT WOULD BE HARMFUL
FOR THE WHOLE ENTERPRISE IF WE
WERE TO DRAMATICALLY IF YOU WILL
CHANGE THE DISTRIBUTION.
SO INSTEAD WHAT WE HAVE BEEN
DOING IS EACH YEAR, TRYING TO
PUT A BIT MORE OF THE FUNDING
INTO THE RPG POOL.
I REALIZE THAT THAT MAY NOT
TOTALLY ANSWER YOUR QUESTION.
>> NO, IT DOES, IT DOES, THANK
YOU.
>> I DON'T SEE ANY OTHER HANDS,
DOUG, ARE THERE ANY OTHER
QUESTIONS FROM THE BSC MEMBERS?
>> SO LET ME JUST CLARIFY THAT
WHEN I SAID X-RAY
CRYSTALLOGRAPHY, I SHOULD HAVE
SAID CRYOEM WHICH THE CRYOEM
FACILITY AT FREDERICK WHICH IS
EXCLUSIVELY FOR THE USE OF THE
EXTRAMURAL COMMUNITY HAS BEEN
EXTREMELY--VERY SUCCESSFUL AND I
HOPE THAT AT LEAST SOME OF YOU
ON THE BSC HAVE TAKEN ADVANTAGE
OF IT.
>> THANK YOU.
WELL IF THERE ARE NO MORE
QUESTIONS, THE ON BEHALF OF THE
BSC MEMBERS, THANK YOU SO VERY
MUCH DOUG FOR PRESENTING TO US
TODAY.